Drug maker Dr Reddy’s Laboratories on Friday said a US district court issued a judgment in its favour as it ruled that the proposed generic version of Suboxone sublingual film does not infringe US patent as asserted by Indivior.
Suboxone (buprenorphine and naloxone) sublingual film is indicated for the maintenance treatment of opioid dependence.
“…on August 31, 2017, the United States District Court for the District of Delaware, issued its judgment in favour of the company, ruling that the proposed generic version of Suboxone (buprenorphine and naloxone) sublingual film does not infringe US Patent …as asserted by Indivior,” the drug maker said in a regulatory filing.
“We are pleased with the verdict passed by the US District Court on the patent litigation of the drug Suboxone,” a company spokesperson said.
Reckitt Benckiser which de-merged its pharmaceuticals business as Indivior in December 2014, developed Suboxone sublingual film using MonoSol Rx’s PharmFilm technology.
The US Food and Drug Administration (USFDA) has approved Suboxone film in four strengths.